Gain Therapeutics, Inc. (NASDAQ:GANX) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

Key Points

• Analyst consensus is “Moderate Buy”: Four of five analysts recommend buying Gain Therapeutics, while one rates it a sell. The average 12-month price target is $7.67.
• GANX remains a speculative, small-cap biotech: Shares opened at $1.20, versus a 52-week range of $1.14 to $4.34, with a market capitalization of approximately $52.15 million. The company reported a quarterly loss of $0.11 per share, but beat estimates by $0.03.
• Institutional ownership is limited but growing: Hedge funds and other institutions own 11.97% of the stock, with several firms initiating positions or increasing their stakes. Gain Therapeutics is developing GT-02287, an oral investigational therapy for GBA1-associated Parkinson’s disease.

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) have received an average rating of "Moderate Buy" from the five analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $7.67.

Several equities analysts have weighed in on GANX shares. BTIG Research restated a "buy" rating and set a $5.00 price objective on shares of Gain Therapeutics in a research note on Monday, October 5th. HC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective on shares of Gain Therapeutics in a report on Monday, October 5th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Gain Therapeutics in a research note on Friday, September 4th.

Gain Therapeutics Stock Performance

Shares of Gain Therapeutics stock opened at $1.20 on Thursday. The company has a market cap of $52.15 million, a PE ratio of -2.39 and a beta of 0.19. Gain Therapeutics has a 52 week low of $1.14 and a 52 week high of $4.34. The business has a 50 day moving average price of $1.66 and a 200-day moving average price of $1.87. The company has a quick ratio of 4.36, a current ratio of 4.36 and a debt-to-equity ratio of 0.02.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. Equities analysts anticipate that Gain Therapeutics will post -0.50 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Two Sigma Securities LLC bought a new stake in Gain Therapeutics in the 2nd quarter worth about $26,000. HB Wealth Management LLC bought a new position in shares of Gain Therapeutics during the 2nd quarter worth approximately $26,000. HighTower Advisors LLC bought a new position in shares of Gain Therapeutics during the 2nd quarter worth approximately $35,000. BOKF NA purchased a new position in shares of Gain Therapeutics in the 3rd quarter worth approximately $35,000. Finally, Apollon Wealth Management LLC boosted its stake in shares of Gain Therapeutics by 33.7% in the 1st quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company's stock worth $51,000 after buying an additional 6,675 shares during the last quarter. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc is a biotechnology company focused on developing small-molecule therapies for diseases associated with lysosomal dysfunction, including neurodegenerative and rare disorders. The company's approach is designed to identify compounds that bind to and modulate disease-related proteins, with the goal of restoring their function and addressing underlying disease mechanisms.

Gain Therapeutics' lead investigational program, GT-02287, is an orally administered, brain-penetrant small molecule being developed for GBA1-associated Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.